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College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USASee Article, pages 207–216Cholangiocarcinoma (CCA) is the second most com-
mon primary hepatic malignancy. It is classiﬁed into
intrahepatic and extrahepatic forms, the latter including
perihilar (involvement of right and/or left hepatic ducts
and their union to form the common hepatic duct) and
distal bile duct CCA. Growth patterns are diﬀerentiated
into periductal-inﬁltrating, mass-forming and papillary
or intraductal growth. The diﬀerent forms of CCA are
distinct and diﬀer clinically, aetiologically, pathophysio-
logically and in management [1]. Global incidence rates
of intrahepatic cholangiocarcinoma (ICC) have signiﬁ-
cantly increased while annual incidence rates of the
more common extrahepatic form has remained rela-
tively stable throughout the last four decades [2]. The
prognosis of CCA is devastating with survival of <24
months following diagnosis. The only potentially cura-
tive treatment options currently are surgical. Unfortu-
nately, the majority of patients are diagnosed at an0168-8278/$34.00  2008 European Association for the Study of the Liver.
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protein 5.advanced, unresectable stage due to the initial silent clin-
ical character of this malignancy.
Despite advances in radiologic and laboratory diag-
nostic tests, the diagnosis of ICC remains highly chal-
lenging. It is an adenocarcinoma and as such often
mimics metastasis to the liver. Many clinicians and
pathologists would, therefore, prefer to have an objec-
tive, deﬁnitive approach for the diagnosis of this neo-
plasm. Immunohistochemical markers such as CK7
and CK19 are overexpressed in 100% of cholangiocarci-
nomas [3–5]. However, they are not speciﬁc for this can-
cer and can be expressed by hepatocellular carcinoma
(HCC) or metastatic adenocarcinoma [6]. Therefore,
there is a continued need for new diagnostic markers
with better speciﬁcity.
Nishino et al. report in this issue of the Journal the
identiﬁcation of three genes diﬀerently expressed in
ICC compared to normal hepatic tissue, HCC and
chronic liver disease: claudin-4 (CLDN-4), insulin-like
growth factor-binding protein 5 (IGFBP-5) and bigly-
can (BGN). The utility of using all three markers for
the diagnosis of ICC is impressive with a receiver oper-
ating curve displaying an area under the curve of close
to one (near perfection). However, the interpretation
of their results is limited due the number and choice of
tissues. Initial SAGE-data are obtained from only one
ICC sample and the overall number of ICC samples
was a mere 16. The most important control, metastatic
adenocarcinoma to the liver, is missing from these stud-
ies. Thus, whether these gene products can be used to
positively diagnose ICC and exclude metastasis is not
addressed by this study, this represents a critical
limitation.Published by Elsevier B.V. All rights reserved.
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patients with hepatic colorectal cancer metastases
served as normal liver controls and non-malignant
hepatic tissue samples from HCC patients served as
chronic liver disease control. The generalization of
chronic liver disease is problematic as the molecular
signature likely diﬀers depending upon the aetiology
of the chronic liver disease. ICC is a highly desmo-
plastic, paucicellular tumor, and microdissection
would be preferable in studies which evaluate gene
expression in these tumors. The use of immunohisto-
chemistry to conﬁrm upregulation of the gene prod-
ucts in the cancer cells assuages this latter concern.
Nevertheless, this battery of markers can likely be
employed to diﬀerentiate HCC, and/or mixed tumors
of the liver.
From a scientiﬁc perspective, the results are not
surprising. CLDN-4 belongs to the claudin family
which are components of tight junctions [7]. CLDN-
4 has been reported to be upregulated in a variety
of diﬀerent epithelial malignancies including cholangi-
ocarcinoma and has been linked to invasiveness in
certain cancers [7–11]. Lodi et al. showed that
CLDN-4 is not expressed in normal hepatocytes and
HCC, weakly in cholangiocytes and highly expressed
in cholangiocarcinoma [8]. Hence, the data by Nishi-
no et al. presented in this issue of the Journal conﬁrm
the results of previous studies. However, Lodi et al.
also point out that CLDN-4 expression does not dif-
ferentiate between biliary tract cancers and metastatic
adenocarcinomas. BGN is matrix proteoglycan
important for organization of collagenous tissue
and modulation of cell adhesion. Its overexpression
is characteristic for mesenchymal cells [12] and likely
reﬂects the highly desmoplastic character of cholan-
giocarcinomas.
IGFBP-5 is one of the six members of the IGFBP-
family. IGFBP are important members of the insulin
growth factor (IGF)-axis which can bind IGF-I and
II, and thereby inhibit the interaction of these growth
factors with their receptors. Proteolytic cleavage results
in the release of IGF-I/II followed by receptor binding
and activation. IGFBP-5 can bind to extracellular
matrix proteins which results in a decrease of its IGF
binding aﬃnity. Similarly, IGFBP-5 has been reported
to be upregulated in a variety of diﬀerent malignancies
including breast-, prostate-, ovarian cancer and other
malignancies. Nishino et al.’s observation of IGFBP-5
in ICC is interesting from a biologic perspective.
Recently, it was reported that ICC express the insulin
growth factor-I receptor and elevated biliary IGF-I con-
centration is suggested as a novel marker for identiﬁca-
tion of cholangiocarcinoma in patients with obstructive
cholestasis [13,14]. IGFBP-5 has been reported to func-
tion by diﬀerent IGF-independent and -dependent
mechanisms resulting for example in the enhancementof local growth factors stimulation [15]. Nishino
et al.’s results, therefore, provide further mechanistic
insight into the biology of IGF-I and its regulation in
ICC.
In summary, Nishino et al. have helped to iden-
tify markers which distinguish ICC from HCC and
may provide mechanistic information regarding the
biology of ICC. A comparison of the ﬁndings with
metastatic adenocarcinomas to the liver is needed
before this panel of markers can be used clinically.
Biologically, they form the basis and justiﬁcation
for further functional studies of IGF-I and IGFBP-
5 in ICC. More work is encouraged on the biology
of ICC; it is well within the domain of hepatology,
and as a profession we need to address this cancer
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